The popularity of Sildenafil initially sparked a period of growth for pharma, nevertheless recent shifts present a complicated outlook for shareholders. Lower-cost versions are eroding earnings, and persistent patent https://joycecvlf047329.blogerus.com/63159964/viagra-and-big-pharma-a-precarious-investment